Literature DB >> 2961234

Relation between extent of left ventricular hypertrophy and occurrence of ventricular tachycardia in hypertrophic cardiomyopathy.

P Spirito1, R M Watson, B J Maron.   

Abstract

This study was undertaken to determine whether the occurrence of ventricular tachycardia (VT) in patients with hypertrophic cardiomyopathy (HC) is related to the magnitude and extent of left ventricular (LV) hypertrophy. Extent of LV hypertrophy was assessed using 2-dimensional echocardiography in 30 patients with HC in whom VT had been documented on 24-hour ambulatory electrocardiographic (ECG) monitoring, and the extent of LV hypertrophy in these patients was compared with that of a control group of 61 patients with HC who had normal ambulatory ECG recordings. Severe LV hypertrophy, involving at least 3 of the 4 LV segments, occurred significantly more often in patients with documented VT (16 of 30, 53%) than in those with normal ambulatory ECG findings (13 of 61, 21%; p less than 0.002). Conversely, mild LV hypertrophy, involving only 1 LV segment, occurred significantly less often in patients with VT (5 of 30, 17%) than in the control subjects (32 of 61, 52%; p less than 0.001). Moderate LV hypertrophy, involving 2 of the 4 LV segments, occurred about as frequently in patients with VT (9 of 30, 30%) as in patients with normal ambulatory ECG findings (16 of 61, 26%; p greater than 0.05). In addition, the LV wall thickness index, a quantitative measure of overall extent of LV hypertrophy, was also significantly higher (thereby indicating a greater magnitude of hypertrophy) in patients with documented VT (72 +/- 17 mm) than in those with normal ambulatory ECG recordings (61 +/- 14 mm; p less than 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 2961234     DOI: 10.1016/0002-9149(87)90406-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy.

Authors:  A Selcuk Adabag; Barry J Maron
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

2.  Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; F Cecchi; W J McKenna
Journal:  Br Heart J       Date:  1994-12

3.  Cardiac dysrhythmias in children with idiopathic dilated or hypertrophic cardiomyopathy.

Authors:  G Müller; H E Ulmer; K J Hagel; D Wolf
Journal:  Pediatr Cardiol       Date:  1995 Mar-Apr       Impact factor: 1.655

4.  Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy.

Authors:  X Jouven; A Hagege; P Charron; L Carrier; O Dubourg; J M Langlard; S Aliaga; J B Bouhour; K Schwartz; M Desnos; M Komajda
Journal:  Heart       Date:  2002-08       Impact factor: 5.994

5.  Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias.

Authors:  Hidenobu Terai; Masami Shimizu; Hidekazu Ino; Masato Yamaguchi; Kenshi Hayashi; Kenji Sakata; Masaru Kiyama; Tatsumi Hayashi; Masaru Inoue; Junichi Taki; Hiroshi Mabuchi
Journal:  J Nucl Cardiol       Date:  2003 May-Jun       Impact factor: 5.952

6.  Machine Learning Methods for Identifying Atrial Fibrillation Cases and Their Predictors in Patients With Hypertrophic Cardiomyopathy: The HCM-AF-Risk Model.

Authors:  Moumita Bhattacharya; Dai-Yin Lu; Ioannis Ventoulis; Gabriela V Greenland; Hulya Yalcin; Yufan Guan; Joseph E Marine; Jeffrey E Olgin; Stefan L Zimmerman; Theodore P Abraham; M Roselle Abraham; Hagit Shatkay
Journal:  CJC Open       Date:  2021-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.